The authors developed an algorithm that uses artificial intelligence (AI) to design new active pharmaceutical ingredients. For any protein with a known three-dimensional shape, the algorithm generates the blueprints for potential drug molecules that increase or inhibit the activity of the protein. Chemists can then synthesise and test these molecules in the laboratory.
All the algorithm needs is a protein’s three-dimensional surface structure. Based on that, it designs molecules that bind specifically to the protein according to the lock-and-key principle so they can interact with it.
The new method builds on the decades-long efforts of chemists to elucidate the three-dimensional structure of proteins and to use computers to search for suitable potential drug molecules. Until now, this has often involved laborious manual work, and in many cases the search yielded molecules that were very difficult or impossible to synthesise. If researchers used AI in this process at all in recent years, it was primarily to improve existing molecules.
Now, without human intervention, a generative AI is able to develop drug molecules from scratch that match a protein structure. This groundbreaking new process ensures right from the start that the molecules can be chemically synthesised. In addition, the algorithm suggests only molecules that interact with the specified protein at the desired location and hardly at all with any other proteins. “This means that when designing a drug molecule, we can be sure that it has as few side effects as possible,” the author says.
To create the algorithm, the scientists trained an AI model with information from hundreds of thousands of known interactions between chemical molecules and the corresponding three-dimensional protein structures.
Together with researchers from the pharmaceutical company Roche and other cooperation partners, the team tested the new process and demonstrated what it is capable of. The scientists searched for molecules that interact with proteins in the PPAR class – proteins that regulate sugar and fatty acid metabolism in the body. Several diabetes drugs used today increase the activity of PPARs, which causes the cells to absorb more sugar from the blood and the blood sugar level to fall.
Straightaway the AI designed new molecules that also increase the activity of PPARs, like the drugs currently available, but without a lengthy discovery process. After the researchers had produced these molecules in the lab, colleagues at Roche subjected them to a variety of tests. These showed that the new substances are indeed stable and non-toxic right from the start.
The researchers aren’t now pursuing these molecules any further with a view to bringing drugs based on them to the market. Instead, the purpose of the molecules was to subject the new AI process to an initial rigorous test. The author says, however, that the algorithm is already being used for similar studies at ETH Zurich and in industry. One of these is a project with the Children’s Hospital Zurich for the treatment of medulloblastomas, the most common malignant brain tumors in children. Moreover, the researchers have published the algorithm and its software so that researchers worldwide can now use them for their own projects.
“Our work has made the world of proteins accessible for generative AI in drug research,” the author says. “The new algorithm has enormous potential.” This is especially true for all medically relevant proteins in the human body that don’t interact with any known chemical compounds.
Latest News
Men with gene mutations are…
By newseditor
Posted 17 May
B cell oxidative phosphoryl…
By newseditor
Posted 17 May
Human brain gene therapy us…
By newseditor
Posted 16 May
Small-molecular mimic of a…
By newseditor
Posted 16 May
Centromere structure and ch…
By newseditor
Posted 16 May
Other Top Stories
Unfolding eye protein/s biogenesis
Read more
tBID can directly trigger cell death
Read more
Botox injections may reduce anxiety
Read more
Blood-clotting protein and gum disease
Read more
Genetic risk factors in sudden unexplained death in children (SUDC)
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Obesity-induced blood-brain…
By newseditor
Posted 18 May
CRISPR/Cas9 model of prosta…
By newseditor
Posted 17 May
Modulation of host immunity…
By newseditor
Posted 17 May
Variability in cell divisio…
By newseditor
Posted 17 May
Biallelic BORCS8 variants c…
By newseditor
Posted 17 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar